Lyra Therapeutics files for $58M IPO

March 9, 2020

Lyra Therapeutics, a Phase 2 biotech targeting ear, nose, and throat diseases, filed on Friday with the SEC to raise up to $58 million in an initial public offering.

The Watertown, MA-based biotech, founded in 2005, announced in late January that it had completed a Series C financing which raised $30 million in new funds.

The company’s lead product candidates, LYR-210 and LYR‑220, are being developed for the treatment of chronic rhinosinusitis, an underserved and debilitating condition that affects approximately 14 million patients in the United States alone.

Read the Nasdaq brief